Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Next on the list of largest golden parachutes is Gilead’s Daniel O’Day, who would receive $80.6 million in the event of ...

UnitedHealth Group spent nearly $1.7 million on security for its top executives in 2024, the healthcare conglomerate ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor ...

Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...